Tenderwize
Wróć do wyszukiwania

Open house drug discount agreements Nintedanib

AOK Bayern - Die Gesundheitskasse·München, Germany·Deadline Mar 03, 2028 · 552 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Structured notice only
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Nintedanib, ATC L01EX09

40/100

Ocena szansy

Needs reviewLow complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

40 / 100

Złożoność

20 / 100

Czynniki ryzyka

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Apr 2028
  • Non-exclusive discount agreements for Nintedanib (ATC L01EX09) with pharmaceutical companies in Bavaria.
  • Open-house model: any eligible pharmaceutical company can join without selection.
Pokaż pełne podsumowanie

Open-house model for non-exclusive drug discount agreements for Nintedanib (ATC L01EX09) by AOK Bayern. Not subject to procurement law. Contracts are offered to all interested pharmaceutical companies that meet eligibility criteria. No selection or award criteria. Contracts run from May 2026 to April 2028, with possible early termination. No estimated value provided.

Ryzyka

No estimated contract value or maximum framework value is provided. This makes it impossible to assess the financial op...

Paper submissions require two signed originals sent by mail, and electronic submissions require a qualified electronic...

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Eligibility

  • Eligibility: only pharmaceutical companies; submit signed self-declaration of reliability.

Administrative

  • Submission: either signed paper copy (two originals) or electronically with qualified electronic signature via DTVP portal.
  • Documents: completed and signed contract, annex listing medicines, and self-declaration of reliability.

Wymagania mogą być niepełne.

Zamawiający

Lokalizacja

München, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE811695320

Działalność

Health

Części (1)

LOT-0001

Open house drug discount agreements Nintedanib

Non-exclusive discount agreements for the active substance Nintedanib (ATC L01EX09) under §130a(8) SGB V. All eligible pharmaceutical companies can join. Identical, non-negotiable terms. Contracts run from 01.05.2026 to 30.04.2028. Early termination possible with one month notice. Automatic suspension if a competitive discount contract is concluded.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

DE212, Germany

Czas trwania

Apr 2026 - Apr 2028

Kategoria

Pharmaceutical products

Termin

Deadline Mar 03, 2028

Szczegóły zamówienia

Data publikacji
15 Mar 2026
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
181186-2026

Dokumenty (2)

Dokument zamówienia 1Portal składania ofert 1

Podobne przetargi

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30